诺和诺德周二尾盘大涨7.1%

Group 1 - The core point of the article is that Novo Nordisk (NVO) experienced a significant stock increase of 7.1% following the FDA approval of its weight loss drug Wegovy, which enhances the outlook for the weight loss market [1][2]. Group 2 - The FDA approval of Wegovy is a pivotal event for Novo Nordisk, indicating potential growth opportunities in the weight loss sector [1][2].